Search

Displaying results 5231 - 5240 of 7180 in total
  1. Drug

    Curcumin sulfate

    go.drugbank.com/drugs/DB14635
    Experimental

  2. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  3. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  4. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of

  5. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  6. Drug

    Pegilodecakin

    go.drugbank.com/drugs/DB15162
    Investigational

    Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small

    Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED
  7. Drug

    Cinchophen

    go.drugbank.com/drugs/DB13551
    Experimental

    Categories: Preparations With No Effect on Uric Acid Metabolism
  8. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

  9. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.

  10. Drug

    3-amino-5-phenylpentane

    go.drugbank.com/drugs/DB02869
    Experimental

    This compound belongs to the phenylpropylamines. … These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K